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PCLINICAL RESEARCH Clinical Trials
A Randomized, Double-Blind,
Placebo-Controlled, Dose-Escalation Study of
Intravenous Adult Human Mesenchymal Stem
Cells (Prochymal) After Acute Myocardial Infarction
Joshua M. Hare, MD,* Jay H. Traverse, MD,† Timothy D. Henry, MD,† Nabil Dib, MD,‡
Robert K. Strumpf, MD,‡ Steven P. Schulman, MD,§ Gary Gerstenblith, MD,§
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Objectives Our aim was to investigate the safety and efficacy of intravenous allogeneic human mesenchymal stem cells
(hMSCs) in patients with myocardial infarction (MI).
Background Bone marrow-derived hMSCs may ameliorate consequences of MI, and have the advantages of preparation ease,
allogeneic use due to immunoprivilege, capacity to home to injured tissue, and extensive pre-clinical support.
Methods We performed a double-blind, placebo-controlled, dose-ranging (0.5, 1.6, and 5 million cells/kg) safety trial of
intravenous allogeneic hMSCs (Prochymal, Osiris Therapeutics, Inc., Baltimore, Maryland) in reperfused MI pa-
tients (n  53). The primary end point was incidence of treatment-emergent adverse events within 6 months.
Ejection fraction and left ventricular volumes determined by echocardiography and magnetic resonance imaging
were exploratory efficacy end points.
Results Adverse event rates were similar between the hMSC-treated (5.3 per patient) and placebo-treated (7.0 per patient)
groups, and renal, hepatic, and hematologic laboratory indexes were not different. Ambulatory electrocardiogram
monitoring demonstrated reduced ventricular tachycardia episodes (p  0.025), and pulmonary function testing dem-
onstrated improved forced expiratory volume in 1 s (p  0.003) in the hMSC-treated patients. Global symptom score
in all patients (p  0.027) and ejection fraction in the important subset of anterior MI patients were both significantly
better in hMSCs versus placebo subjects. In the cardiac magnetic resonance imaging substudy, hMSC treatment, but
not placebo, increased left ventricular ejection fraction and led to reverse remodeling.
Conclusions Intravenous allogeneic hMSCs are safe in patients after acute MI. This trial provides pivotal safety and provi-
sional efficacy data for an allogeneic bone marrow-derived stem cell in post-infarction patients. (Safety Study of
Adult Mesenchymal Stem Cells [MSC] to Treat Acute Myocardial Infarction; NCT00114452) (J Am Coll Cardiol
2009;54:2277–86) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.055n
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Sell-based therapies for myocardial infarction (MI) are
urrently under evaluation and are emerging as a promising
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Allogeneic hMSC Safety and Efficacy in AMI December 8, 2009:2277–86tion fraction (2–4) and other
clinical markers (3,5,6). The use
of BMCs is limited, however, by
the need to obtain a bone mar-
row aspirate from each individual
patient, and may be further com-
plicated by host factor variability
in the quality and ability of the
BMCs to achieve the desired ef-
fects (7).
See page 2287
Pre-cultured bone marrow-
derived human mesenchymal stem
cells (hMSCs) represent an alter-
native approach to cardiovascular
cell therapy that has a number of
advantages when compared with
autologous BMCs (8). First, MSCs
an be infused intravenously post-MI due to their ability to
ome to areas of injury within the myocardium, stimulated, at
east in part, by the SDF-1/CXCL12 axis (9,10). Second, they
ay be used as an allogeneic graft as they lack various major
istocompatibility complex and costimulatory cell-surface an-
igens, and secrete anti-inflammatory cytokines. Finally, they
epresent an enriched population of cells with therapeutic
roperties, as demonstrated in pre-clinical studies (8). While
he use of these cells is highly promising and supported by
re-clinical studies, there are also safety concerns regarding
heir application, including concerns regarding tumor (11),
ctopic tissue formation (12), and organ toxicity resulting from
nwanted lodgment in the microvasculature (13).
To address these concerns, and to establish a basis for
uture efficacy trials, we performed a double-blind, placebo-
ontrolled, dose-ranging study of allogeneic adult bone
arrow-derived hMSCs in patients after an acute MI. The
urpose of this trial was to assess the safety profile of
llogeneic hMSCs administered intravenously to patients
fter acute MI.
ethods
rial design. This study was a phase I randomized,
ouble-blind, placebo-controlled, dose-escalation, multi-
enter trial to evaluate the safety of allogeneic bone marrow-
erived hMSC administration for patients experiencing a
rst acute MI. A total of 53 patients enrolled at 10
articipating study centers completed the trial through the
-month time point, with safety and exploratory efficacy end
oints evaluated at 1-, 2-, 3-, and 6-month follow-up visits.
he trial was conducted in compliance with current Good
linical Practice standards and in accordance with the
rinciples set forth under the Declaration of Helsinki
1989). Institutional review board approvals of the treat-
ent protocol were obtained at all centers before the
Abbreviations
and Acronyms
AE  adverse event
BMC  bone marrow
mononuclear cell
FEV1  forced expiratory
volume in 1 s
hMSC  human
mesenchymal stem cell
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
MRI  magnetic resonance
imaging
PVC  premature
ventricular contraction
VT  ventricular
tachycardianitiation of patient enrollment. All patients entering the crial agreed to and signed an institutional review board-
pproved statement of informed consent.
omposition of active investigational agent and placebo
uspension. The active investigational agent was hMSCs
solated from bone marrow aspirates obtained from a single
nrelated donor who was not human-leukocyte-antigen–
atched to recipients. The hMSCs in Prochymal (Osiris
herapeutics, Inc., Baltimore, Maryland) were manufac-
ured in a manner consistent with International Conference
n Harmonization and Food and Drug Administration
egulatory guidelines. The donor was tested according to the
ood and Drug Administration Donor Suitability Guidance
efore donation. The phenotype of the hMSC population
as characterized by a cell-surface profile of CD105,
D166, and CD45. The infused Prochymal formulation
onsists of 2.5  106 hMSCs/ml, 1.9% human serum
lbumin, and 3.8% dimethyl sulfoxide in PlasmaLyte A
Baxter, Deerfield, Illinois). Patients assigned to placebo
roups received a solution of 1.9% human serum albumin
ith 3.8% dimethyl sulfoxide in PlasmaLyte A. Release
esting of the cells included measurement of cell-surface
arkers CD105 and CD166, absence of CD45, testing for
ycoplasma, sterility, endotoxin, identity, purity, and via-
ility and karyotyping to exclude chromosomal abnormali-
ies. The final viability was at least 70% viable MSCs, as
etermined by Trypan blue (generic) testing. During the
ourse of this cardiac study, the hMSC preparation under
valuation was referred to as “Provacel,” which is the same
nvestigational agent as Prochymal, a highly purified prep-
ration of ex vivo cultured adult hMSCs.
reatment groups and infusion parameters. All patients
eceived a single intravenous infusion of Prochymal or
lacebo suspension delivered at a rate of 2 ml/min. The
afety and tolerability of Prochymal infusion were evaluated
n 3 placebo-controlled dose escalation cohorts of 0.5, 1.6,
nd 5.0  106 hMSCs/kg body weight. Subjects were
andomly assigned in a double-blind fashion to each cohort
n a 2:1 ratio of Prochymal to placebo. Intravenous tubing
as coated with an opaque wrap so as to obscure any
dentifying features of the infusion. All patients in each of
he cohorts met identical inclusion and exclusion criteria.
he cohorts were enrolled sequentially. Advancement to the
ext dose cohort was contingent on an unblinded review of
afety data accumulated to that date by an independent Data
afety and Monitoring Board.
atient population. To be eligible for trial entry, patients
ust have had a first MI (either ST-segment elevation or
on–ST-segment elevation) 1 to 10 days before randomiza-
ion. All patients were required to have a patent infarct-
elated artery on coronary angiography at the time of
andomization. Angiographic measures included epicardial
lood flow and myocardial perfusion, as assessed by Throm-
olysis In Myocardial Infarction (TIMI) flow grade (14)
nd TIMI myocardial perfusion grade (15), respectively.
The index MI for all patients enrolled met the following
riteria: 1) elevation of 2 upper limit of normal of
reatine kinase-MB or troponin; 2) presence of regional wall
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December 8, 2009:2277–86 Allogeneic hMSC Safety and Efficacy in AMIotion abnormality; and 3) global left ventricular ejection
raction (LVEF) of 60% and 30% as determined by
6-segment echocardiogram or ventriculogram.
A total of 60 subjects were screened for enrollment in the
rial, of which 53 were treated with the investigational agent
r placebo. The Data Safety and Monitoring Board ap-
roved enrollment of each escalating dose cohort, and an
dditional cohort was enrolled at the highest dose. Patient
nrollment occurred between March 2005 and March 2006.
All patients were hemodynamically stable before random-
zation, defined as the absence over a 24-h period of: 1) the
eed for parenteral inotropic support; 2) systolic blood
ressure 80 mm Hg for longer than 1 h; and 3) resting
eart rate 100 beats/min for longer than 1 h. Adequate
ulmonary function to meet entry criteria was defined as a
orced expiratory volume in 1 s (FEV1) 50% predicted
nd peripheral artery oxygen saturation 97%. At enroll-
ent, all patients had Karnofsky performance status scores
f 60.
Patients were not enrolled in the trial if revascularization
ia coronary artery bypass surgery was required or if the
hysician anticipated further coronary revascularization pro-
edures during the 6-month study period. Patients with
linically significant primary valvular heart disease or evi-
ence of life-threatening arrhythmia on baseline electrocar-
iogram (ECG) were also excluded.
atient enrollment and randomization. Patients were
nrolled by study investigators. Randomization, stratified by
ose cohort, was conducted in a centralized manner and
ommunicated to cellular therapy laboratory personnel.
ubjects were randomly assigned to either Prochymal or
lacebo in a 2:1 ratio within each cohort. Manual random-
zation was performed using sealed envelopes.
ssessments. Physicians and other clinical personnel re-
ained blinded to treatment assignment for all patients
hroughout the study period. Primary safety assessments
ncluded monitoring and recording of all adverse events
AEs) and serious AEs. Safety laboratory and urine values,
egular vital sign measurements, and physical examination
esults were recorded as well. Peripheral artery blood oxygen
aturation during Prochymal infusion was monitored by
ulse oximetry. To follow the occurrence of post-infusion
rrhythmias, 12-lead ECGs, 24-h ambulatory ECG record-
ng, and telemetry monitoring were performed. Telemetry
as performed continuously in the 4 days after the proce-
ure, and patients received 24-h ambulatory monitoring at
he 1-, 2-, 3-, and 6-month follow-up visits. Nonsustained
entricular tachycardia (VT) was defined as 3 consecutive
eats at a rate of 100 beats/min. Contrast-enhanced
omputed tomography scans of the chest, abdomen, and
elvis were utilized to identify any evidence of ectopic tissue
ormation.
A 16-segment echocardiography was performed to assess
VEF. Multiple views were recorded, including the sub-
ostal, parasternal long- and short-axis, and apical 2- and
-chamber views. Parasternal short-axis views were re-
orded at the basal (mitral valve level), mid (papillary muscle gevel), and apical positions. Subject angulation and trans-
ucer position were recorded for serial examinations. Con-
rast administration was used for enhancement of the
ndocardial border. End-diastolic wall thickness was mea-
ured from the parasternal long- and short-axis views. Wall
otion analysis was performed using the 16-segment model
roposed by the American Society of Echocardiography
16). Each wall segment was scored using a visual grading
ystem (1  normal, 2  hypokinetic, 3  akinetic, 4 
yskinetic, and 5  aneurysmal). The wall motion score
ndex, defined as the average wall motion score for all
egments divided by the number of segments analyzable,
as determined for each reading. The percentage of wall
otion abnormalities was obtained by dividing the number
f akinetic, dyskinetic, and aneurysmal segments by the total
umber of segments evaluated. Left ventricular volumes
ere determined at end-diastole and -systole. Endocardial
orders were manually traced from apical 4- and 2-chamber
iews, and the volumes obtained were used to calculate
VEF using the biplane summation-of-disks method rec-
mmended by the American Society of Echocardiography
16).
A cardiac magnetic resonance imaging (MRI) substudy
as performed in a subset of patients. MRI was carried out
efore hMSC or placebo infusion, after primary coronary
ntervention, and during the 3- and 6-month follow-up
isits. An additional 12-month cardiac MRI was obtained
nd is also reported here. Baseline MRI scans were limited
o nonstress evaluations. MRI scans were evaluated offline at
n imaging core (the Netherlands). LVEF was measured
ccording to the validated National Heart, Lung, and Blood
nstitute-Laboratory of Cardiac Energetics laboratory stan-
ard (17), using contiguous short-axis slices obtained by
ine MRI. End-diastolic and -systolic endocardial traces
ere used to determine end-systolic and -diastolic left
entricular volumes and total ejection fraction.
To assess pulmonary function, spirometry tests were
erformed throughout the 6-month period after treatment.
hese evaluations were carried out according to American
horacic Society guidelines (18). Predicted values for FEV1
ere calculated using published formulae (19).
A 6-min walk test was performed at randomization and
uring follow-up visits. The procedure for the 6-min walk
est followed the American Thoracic Society guidelines
20). Distance walked in 6 min along a 30-m (100-ft)
allway was recorded.
A global assessment of overall patient health was deter-
ined by the investigator from subject interviews at day 10
nd during the 6-month period after treatment. Global
tatus of the subject was evaluated relative to pre-treatment
sing the following categorical ratings: improved, un-
hanged, and worsened.
ata collection. All data were recorded on case report
orms and verified by comparison with source documenta-
ion by third-party medical monitors. Incidence summaries
re reported as subject counts and percent of treatment
roup. Safety assessments based on the frequency of AEs
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Allogeneic hMSC Safety and Efficacy in AMI December 8, 2009:2277–86nd on clinically significant abnormal laboratory values were
erformed. AEs are summarized as the number and per-
entage of subjects experiencing an AE within each treat-
ent group.
tatistical analysis. Summaries of continuous measures are
resented as the mean and SD. Proportional analyses were
sed to identify differences in premature ventricular con-
raction (PVC) incidence and global assessment. Statistical
ignificance in proportional differences (Tables 1 and 2) was
nalyzed using the Fisher exact test (2-tailed). Where
ndicated, measures of clinical efficacy are reported as the
ercent change from baseline evaluation. Echocardiographic
nd 6-min walk data are presented with means and 95%
onfidence intervals. Comparisons of changes from baseline
onditions were analyzed using the Student t test (2-tailed,
aired). Statistical differences in averaged group results were
ompared by Student t test (2-tailed, homoscedastic) with
atient Demographics and Primary Baseline DataTable 1 Patient Demographics and Primary Baseline Data
hMSC Placebo p Value
Randomized 39 21
Completed 34 (87.2%) 19 (90.5%) 1.000
Age, yrs 59.0 (12.3) 55.1 (10.2) 0.244
Male 28 (82.4%) 15 (78.9%) 1.000
Race/ethnicity
Caucasian 30 (88.2%) 16 (84.2%) 0.691
Hispanic 3 (8.8%) 2 (10.5%) 1.000
Asian 1 (2.9%) 1 (5.3%) 1.000
BMI, kg/m2 29.8 (6.7) 30.3 (4.3) 0.800
Obesity 4 (11.8%) 0 (0%) 0.284
Diabetes 6 (17.6%) 1 (5.3%) 0.400
Hypertension 16 (47.1%) 9 (47.4%) 1.000
Current smoker 3 (8.8%) 2 (10.5%) 1.000
Former smoker 1 (2.9%) 2 (10.5%) 0.290
Target/index vessel
LAD 15 (44.1%) 9 (47.4%) 1.000
RCA 13 (38.2%) 5 (26.3%) 0.547
Obtuse marginal 2 (5.9%) 1 (5.3%) 1.000
Diagonal 2 (5.9%) 0 (0.0%) 0.531
Circumflex 2 (5.9%) 1 (5.3%) 1.000
LAD/diagonal 0 (0.0%) 1 (5.3%) 0.359
LAD/RCA 0 (0.0%) 1 (5.3%) 0.359
RCA/circumflex 0 (0.0%) 1 (5.3%) 0.359
Time to reperfusion, h 9.8 (10.4) 11.7 (14.2) 0.578
Baseline LVEF, % 50.4 (10.6) 48.7 (9.6) 0.571
TIMI risk score 3.6 (2.2) 2.8 (1.3) 0.206
TIMI myocardial
perfusion grade
2.3 (1.1) 2.4 (1.1) 0.828
TIMI flow grade 2.5 (1.0) 2.7 (1.0) 0.467
FEV1, % predicted 74.0 (15.6) 76.7 (17.6) 0.566
CK-MB (g/l)
Average 134.6 (125.4) 160.1 (131.9) 0.490
Low 3.2 5.3
High 429.1 457
ST-segment elevation, % 79.4 68.4 1.000
alues are presented as n, n (%), or mean (SD).
BMI  body mass index; CK-MB  creatine kinase-MB; FEV1  forced expiratory volume in 1 s;
MSC  human mesenchymal stem cell; LAD  left anterior descending coronary artery; LVEF r
eft ventricular ejection fraction; RCA  right coronary artery; TIMI  Thrombolysis In Myocardial
nfarction.he Bonferroni correction. Where multiple comparisons
ere performed, analysis of variance (ANOVA) with re-
eated measures and Student-Newman-Keuls post-hoc
esting was employed for within-group analysis and
etween-group (treatment vs. placebo) comparisons used
-way ANOVA with terms for group and a group  time
nteraction term. Where appropriate, post-hoc analysis with
he Bonferroni correction was applied. Testing was per-
ormed at a 95% significance level.
esults
atients. Demographic and baseline patient data are listed
n Table 1 and Figure 1 and demonstrate similar distribu-
ions of age, sex, race, and body mass index; prevalences of
besity, diabetes, smoking, and hypertension; and time
ost-MI to infusion in the patient groups. Baseline LVEF,
IMI risk score, and FEV1 were also similar at trial entry
or those patients assigned to active therapy or placebo
nfusion.
Es. Over the course of the study, 313 AEs were recorded
Table 2). There was no trend within any AE class that
ndicated a propensity toward an increased incidence in the
ell-treated group. No significant trends in AE incidence or
n efficacy results were identified among the different dosing
ohorts. Accordingly, safety and efficacy data for all 3
MSC dose cohorts and all placebo cohorts are combined in
his report. There was no evidence of increased toxicity with
he administration of hMSCs compared with placebo, and
dministration was well tolerated at all cell dose levels.
here were no deaths during the study, and no subjects
iscontinued from study treatment because of an AE. In
ddition, no AEs were considered to have a probable
elation to study treatment.
There was no evidence of an increased incidence of
ctopic tissue growth determined using whole body com-
uted tomography scanning. In a few cases (2 in the
ell-treated and 1 in the placebo group), evidence of
re-existing ectopic tissue masses present at baseline were
oted by the investigator.
AE rates in hMSC-treated patients were not greater than
n placebo-treated patients (5.3 vs. 7.0 AEs per patient,
espectively) (Table 2). Furthermore, the serious AE rate
as 23.5% (n  9 events in 8 subjects) in the hMSC group
nd 31.6% (n 7 events in 6 subjects) in the placebo group.
similar nonstatistical trend was observed with regard to
ospitalization rates (Table 2), which was 31.6% at an
verage of 66 days after discharge in the placebo group
ersus 23.5% at an average of 120 days after discharge in the
MSC group.
rrhythmias. Specific safety monitoring of arrhythmias
uring the course of the trial revealed improved outcomes in
he hMSC-treated group compared with the placebo group.
ll patients enrolled in the trial underwent ambulatory
onitoring to detect the occurrence of any cardiac arrhyth-
ias. The arrhythmia event rate in the patients whoeceived hMSCs was 4-fold lower than that in the patients
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December 8, 2009:2277–86 Allogeneic hMSC Safety and Efficacy in AMIho received placebo (8.8% vs. 36.8%, p  0.025, Fisher
xact test) (Table 2).
Consistent with findings related to arrhythmic events in
eneral, similar results were observed with regard to the
requency of VT and number of PVCs recorded for hMSC-
ersus placebo-treated patients. Only a single patient (2.9%)
n the hMSC-treated group, versus 6 episodes in 5 patients
26.3%) in the placebo group, experienced VT (p  0.018).
ubjects treated with hMSCs also had fewer PVCs at all
ime points after day 10 (Fig. 2). The percentage of patients
ho experienced more than 10 PVCs per hour for all time
Figure 1 Time After MI to Infusion of Study Agent
Human mesenchymal stem cells  solid bars;
placebo  open bars. MI  myocardial infarction.
AEs and Rehospitalization SummaryTable 2 AEs and Rehospitalization Summary
Total AEs
Average AEs per patient
Subjects with at least 1 AE
Cardiac disorders
Gastrointestinal disorders
General disorders and administration site conditions
(chest pain, fatigue, and so on)
Immune system disorders
Infections and infestations
Rehospitalizations
Total
Average per patient
Subjects requiring at least 1 rehospitalization
Average time to rehospitalization, days
Arrhythmias
Arrhythmic events
Subjects with at least 1 arrhythmic event
Ventricular tachycardia
Values are presented as n or n (%).
AE  adverse event; hMSC  human mesenchymal stem cell.oints in the trial was also significantly less in those patients
ho received hMSCs as compared with those who received
lacebo (10% vs. 24%, p 0.001). This difference was most
ronounced at 1 (6% vs. 32%, p 0.040) and 2 months (9%
s. 38%, p  0.043) after MI.
chocardiographic data. Echocardiography revealed im-
rovements in LVEF in hMSC-treated patients (Table 3).
aseline LVEF was similar between patient groups (50.4%
n Provacel-treated patients, n  34, and 48.7% in placebo-
reated patients, n  19; p  0.561). Overall, patients
reated with hMSCs experienced a 5.9  1.8% increase in
VEF at 3 months (p  0.003 vs. baseline, n  33)
ompared with a 4.4  1.8% increase in the placebo group
Figure 2 Percentage of Patients With >10 PVCs per Hour
Human mesenchymal stem cells  green line (n  32 at 3 months, n  33
at 6 months); placebo  red line (n  19 at 3 months, n  16 at 6 months).
*p  0.001 by repeated measure analysis of variance; †p  0.05 versus days 1
and 90; ‡p  0.017 versus placebo. PVC  premature ventricular contraction.
hMSC Placebo p Value
181 132
5.3 7.0
33 (97.1) 19 (100.0) 1.000
15 (44.1) 9 (47.4) 0.999
9 (26.5) 4 (21.1) 0.749
14 (41.2) 13 (68.4) 0.086
2 (5.9) 0 (0) 0.531
11 (32.4) 5 (26.3) 0.760
9 7
0.26 0.37
8 (23.5) 6 (31.6) 0.535
120 66
7 12
3 (8.8) 7 (36.8) 0.025
1 (2.9) 5 (26.3) 0.018
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Allogeneic hMSC Safety and Efficacy in AMI December 8, 2009:2277–86p 0.021 vs. baseline, n 19). This effect was maintained
hrough 6 months, at which time LVEF was increased by
.7  2.2% over baseline in hMSC-treated patients (p 
.004 vs. baseline, n  30). The 6-month echocardio-
raphic ejection fraction was not different between placebo-
nd cell-treated patients (Table 3).
When only patients with anterior wall MIs were exam-
ned, the impact of cell therapy relative to placebo was more
ronounced (Fig. 3): patients treated with hMSCs had a 7.0
.5% point improvement in LVEF at 3 months (p  0.056
s. baseline, n  14) and a 7.3  3.4% increase at 6 months
elative to baseline (p  0.044, n  12). In contrast,
ncreases in ejection fraction in the placebo group, 2.9 
.5% at 3 months and 3.4  3.4% at 6 months, were not
tatistically significant (p  NS for both time points; n  9
t 3 months, n  8 at 6 months).
There were no significant differences between hMSC-
nd placebo-treated patients with regard to measures of wall
hickness, wall motion score index, and percentage of wall
otion abnormalities at baseline. Over the follow-up pe-
iod, evidence of prevention of wall thinning and reduction
n percentage of wall motion abnormalities was observed in
MSC-treated patients (data not shown).
RI substudy. Cardiac MRI was performed in a subgroup
f patients (n  20 hMSC and n  14 placebo). Baseline
VEF was similar in hMSC and placebo patients (47.3 
.3% and 45.2  3.4%, respectively). MRI evaluation
evealed a progressive increase in LVEF relative to baseline
t 3 and 6 months in hMSC- but not in placebo-treated
atients (Table 4, Fig. 4). Moreover, this difference contin-
ed through the 12-month follow-up evaluation, at which
ime LVEF had increased by 5.2  1.9% (p  0.003, by
epeated measure ANOVA). LVEF in the placebo-treated
atients did not increase, and the difference in change
etween groups was not significant. MRI also allows precise
easurement of left ventricular chamber volumes: when
lotted relative to ejection fraction, hMSC patients exhib-
ted evidence of reverse remodeling with no increase in left
entricular end-diastolic volume and a decline in left ven-
Ejection Fraction and 6-Min Walk TestTable 3 Ejection Fraction and 6-Min Walk T
hMS
Mean (95
Ejection fraction (all patients), %
Baseline 50.4 (46.9
3 months 56.7 (54.0
6 months 56.9 (53.3
Ejection fraction (anterior MIs), %
Baseline 48.3 (42.0
3 months 55.9 (51.7
6 months 55.1 (50.4
6-min walk, distance walked, ft
Baseline 1,145 (1,03
3 months 1,437 (1,32
6 months 1,490 (1,38
CI  confidence interval; hMSC  human mesenchymal stem cell; MIricular end-systolic volume, whereas placebo patients dem-nstrated evidence of left ventricular chamber enlargement
Table 4, Figs. 5A and 5B). The changes in ejection fraction
nd end-systolic volume did not correlate with baseline
nd-systolic volume (r  0.316, p  0.10).
ulmonary function. Pulmonary function tests were per-
ormed to monitor subjects for potential adverse changes
elated to study treatment. Figure 6 shows the average change
n FEV1 percent predicted in trial subjects over time. Com-
ared with patients receiving placebo, those treated with
MSCs showed a greater increase in percent predicted FEV1,
elative to baseline values, from 3 days through the 6 months
ost-infusion. At 10 days, this difference in the increase in
ercent predicted FEV1 observed for hMSC versus placebo
atients was statistically significant (p  0.01, Bonferroni).
Figure 3
Increase From Baseline Values
in Percent LVEF at 3 and 6 Months
Post-Treatment in Patients With Anterior MI
Human mesenchymal stem cells  solid bars (n  17 at 3 months, n  15 at
6 months); placebo  open bars (n  10 at 3 months, n  9 at 6 months).
*p  0.0436 at 6 months for human mesenchymal stem cell-treated patients
versus baseline, analysis of variance. LVEF  left ventricular ejection fraction;
MI  myocardial infarction.
Placebo
Mean (95% CI) p Value
48.7 (44.4–53.1) 0.561
53.1 (49.8–56.4) 0.108
56.1 (53.3–58.9) 0.737
53.2 (48.6–57.8) 0.225
56.1 (51.6–60.7) 0.937
57.0 (53.1–60.9) 0.549
4) 1,074 (931–1,218) 0.443
8) 1,310 (1,143–1,477) 0.220
9) 1,401 (1,217–1,584) 0.419
cardial infarction.est
C
% CI)
–54.0)
–59.3)
–60.5)
–54.5)
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December 8, 2009:2277–86 Allogeneic hMSC Safety and Efficacy in AMIurthermore, the 16% improvement in hMSC-treated pa-
ients at 6 months post-infusion was statistically significant
hen compared with the baseline values (p  0.003, by
epeated measure ANOVA).
-min walk. Six-min walk data are presented in Table 3. As
ndicated, walk duration did not differ between the 2 groups.
lobal assessment. The overall health of study subjects was
ollowed by investigators during the course of the trial for signs
f improvement or deterioration. In this global assessment of
atient health, hMSC-treated patients received higher scores
han did patients in the placebo group at all time points
nalyzed (Fig. 7). Significantly more patients in the hMSC
roup were judged to have improved overall condition at 6
onths as compared with those receiving placebo (42% vs.
1%, p  0.027, Fisher exact test). While the proportion of
MSC-treated patients reported by their physicians as im-
roved remained consistently high throughout the study, the
roportion of patients in the placebo group that were judged
mproved steadily decreased, from 47% at 10 days to 11% at 6
onths (p  0.016, Fisher exact test).
ose-response. When analyzed for dose-dependent ef-
ects, the parameter that exhibited clear dose-responsiveness
as PVC count, which did not differ between the placebo
nd low-dose cell groups, but was evident in the mid- and
Figure 4 Impact of hMSC Treatment
on LVEF Evaluated by Cardiac MRI
Human mesenchymal stem cells (hMSCs)  green line (n  21 at 3 months,
n  18 at 6 and 12 months); placebo  red line (n  13 at 3 months, n 
11 at 6 and 12 months). *p  0.003 by repeated measure analysis of vari-
ance; †p  0.005 versus baseline. Abbreviations as in Figure 3.
RI Findings at Baseline and Absolute Changes at 3, 6, and 12 MTable 4 MRI Findings at Baseline and Absolute Changes at 3,
Baseline
hMSC Placebo
Ejection fraction, % 47.3 1.7 45.1 1.7
End-diastolic left ventricular volume, ml 180.6 11.5 202.0 14.7
End-systolic left ventricular volume, ml 95.3 7.1 112.6 10.4 
p  0.005 versus baseline.
hMSC  human mesenchymal stem cell; MRI  magnetic resonance imaging.igh-dose groups. All other parameters examined did not
xhibit dose-responsiveness.
iscussion
his double-blind, placebo-controlled, randomized, dose-
anging phase I study reports on the first use of allogeneic bone
Figure 5 Impact of hMSC Treatment on LV Remodeling
Changes in left ventricular (LV) ejection fraction (EF) are plotted against the
changes in LV end-systolic volume (ESV) (A) and end-diastolic volume (EDV)
(B) during follow-up. Human mesenchymal stem cell (hMSC) patients (n  21
at 3 months, n  18 at 6 and 12 months) exhibit evidence of reverse remodel-
ing with no increase in LV EDV and a decline in LV ESV, whereas placebo
patients (n  13 at 3 months, n  11 at 6 and 12 months) demonstrate evi-
dence of LV chamber enlargement. *p  0.005 versus baseline.
(Mean  SEM)d 12 Months (Mean  SEM)
ge at 3 Months Change at 6 Months Change at 12 Months
Placebo hMSC Placebo hMSC Placebo
1.7 0.1 1.8 2.2 1.6 0.7 1.9 5.2 1.9* 1.8 1.5
5.0 7.9 12.0 9.3 6.5 14.0 9.3 2.8 8.1 10.2 9.9
3.2 5.8 9.5 2.8 4.6 10.2 8.2 4.3 6.6 2.4 6.6onths6, an
Chan
hMSC
2.6
1.9
3.2
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Allogeneic hMSC Safety and Efficacy in AMI December 8, 2009:2277–86arrow-derived hMSCs for the treatment of patients after
cute MI. The study met its primary objective demonstrating
afety of intravenous infusion of allogeneic hMSCs during the
nfusion and during short- and longer-term follow-up. In
ddition, the results of this study provide provocative,
reliminary indications that this therapy has clinical efficacy.
n 4 specific areas of pre-specified safety monitoring—
ardiac arrhythmias, pulmonary function, cardiac perfor-
ance, and patient global symptomatic status—the treated
atients exhibited significantly improved outcomes relative
o the placebo group, consistent with a therapeutic benefit.
The present results advance the growing field of cell-based
herapies for adult organ injury. Supported by findings in
nimal models, a number of clinical trials have been conducted
sing autologous BMCs administered by intracoronary infu-
ion to patients after MI (3,6,21). While a full consensus is
acking (22), the totality of findings from these clinical trials
upports the hypothesis that BMC infusion yields a small but
ignificant increase in ejection fraction (2). Importantly, the
EPAIR-AMI (Reinfusion of Enriched Progenitor Cells and
nfarct Remodeling in Acute Myocardial Infarction) study also
uggests that this therapeutic approach has clinical benefits,
ncluding a reduction in the composite of mortality, revascu-
arization, and heart failure hospitalizations (3).
There are significant limitations to the development of
MCs as a therapy for patients with cardiac disease. First,
he active cellular constituent of bone marrow that is the
gent of repair is not well characterized. Second, it is widely
stimated that therapeutically active bone marrow constit-
ents likely represent only 1 in 10,000 bone marrow cells
9). Third, obtaining bone marrow requires an invasive
rocedure, and fourth, concerns exist that patients most
ikely to be affected by coronary atherosclerosis are also the
Figure 6 Difference From Baseline in FEV1 % Predicted
Human mesenchymal stem cells  green line (n  31); placebo  red line
(n  18). Error bars represent standard error of the mean. *p  0.003 by
repeated measure analysis of variance; †p  0.01 versus placebo. FEV1 
forced expiratory volume in 1 s.ost likely to have impaired bone marrow function (7).The use of allogeneic hMSCs has a number of important
dvantages. They likely represent an enriched population of
ells with therapeutic capacity. They are readily prepared
rom healthy donors and may be used as an allogeneic, and
hus “off-the-shelf” agent. They are easy to administer, as
videnced by the intravenous approach used in this study.
inally, and most compelling, there are a wealth of pre-
linical data in rodent (23) and larger animal (24–29)
odels supporting their efficacy in cardiac repair.
This study assessed ejection fraction and left ventricular
hamber volumes in hMSC-treated and placebo patients
sing echocardiography and, in a substudy, cardiac MRI. In
he entire study group, ejection fraction increased at 3
onths after therapy and remained elevated at 6 months. A
imilar increase was observed in the BOOST (Bone Marrow
ransfer to Enhance ST-Elevation Infarct Regeneration)
tudy, albeit at longer follow-up periods. In addition, the
OOST study also revealed a catch-up phenomenon similar
o that observed in our echocardiographic study, in which
jection fraction in the placebo group eventually reaches the
evel seen in the cell-treated group (21). In the important
ubgroup of anterior MI patients, the increase in ejection
raction in the treated group was more evident relative to the
lacebo patients. Importantly, these data are provisional, but
o suggest that future studies should focus attention on
atients with larger infarctions.
When we used the more sensitive cardiac MRI technique in
subset of patients, only treated patients showed a significant
ncrease in LVEF, which was sustained throughout 12 months
f follow-up. In addition, cardiac MRI suggested that hMSC-
reated patients exhibit evidence of favorable, reverse remod-
ling in contrast to placebo patients who exhibited progressive
hamber enlargement. These differences were not significant,
ossibly due to the low number of test subjects, but the
ndings support a direct cardiac effect of intravenous hMSCs,
ith additional experimental work required to substantiate this
Figure 7 Percentage of Patients
With Improved Global Assessment
Human mesenchymal stem cells  green line; placebo  red line. *p  0.027
between groups, Fisher exact test; †p  0.016 versus day 10, Fisher exact test.
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December 8, 2009:2277–86 Allogeneic hMSC Safety and Efficacy in AMIoncept (5). Concerns have been raised that murine MSCs
ultured in excess of 8 passages develop reduced telomere
ength, develop chromosomal abnormalities, and induce tu-
ors in animal models (11,30). To address this issue, the cells
dministered in this study were scrutinized for normal karyo-
ype and were prepared with 5 passages. Extensive pre-clinical
esting was performed, which failed to reveal tumor formation
n cell-treated animals. Importantly, this study specifically
ncorporated chest, abdomen, and pelvic computed tomogra-
hy scanning, and, during the study period, no evidence of
ctopic tissue formation was observed. All patients in this study
re also undergoing an additional 18 months of follow-up, 24
onths total.
Pre-clinical studies indicate that a large proportion of
nfused cells initially distribute to the lungs after administration
31), raising potential concerns regarding compromised pul-
onary function. The results of this study showed no evidence
f a pulmonary safety risk after infusion of hMSCs. Instead,
he data presented here reveal improved pulmonary function in
he hMSC-treated patients, compared with baseline status.
he timing of improvement in lung function, beginning
hortly after administration, suggests a locally active beneficial
MSC-mediated effect on pulmonary airways.
This study extends the use of allogeneic hMSC therapy to
atients with recent acute MI and is the first report of the
se of these cells in that setting. Systemic delivery of
llogeneic hMSCs has been evaluated previously and is
urrently being studied in patients with graft versus host
isease (32), osteogenic imperfecta (33), and glycogen
torage diseases (34).
While the present results provide reassurance regarding the
afety of allogeneic hMSCs for cardiac disease, significant work
s required to understand the mechanism of action of this
pproach. hMSCs are reported to differentiate into cardiac
yocytes in vitro and, as such, may contribute to replacing lost
yocytes after MI (35). hMSCs may also contribute to cardiac
epair after MI through the release of locally acting factors (36),
hich could inhibit infarct scar expansion and stimulate
asculogenesis, cardiogenesis, and the recruitment of additional
ells to the injured area. Additionally, hMSCs have the
otential to stimulate endogenous healing by recreating cardiac
tem cell niches (35,37,38). Work is underway to further
elineate the mechanism of action of hMSC therapy after
ardiac injury.
This study offers some potential clinical insights. As the
rimary goal of the study, potential safety concerns are allevi-
ted by the present findings. Importantly, the intravenous
nfusion did not compromise, but appeared to improve lung
unction, and ectopic tissue formation did not occur. Finally,
his work forms the basis for future clinical trials and mecha-
istic studies aimed at establishing the therapeutic possibility of
nfusing hMSCs post-acute MI to improve left ventricular
unction and reduce infarct-related injury. Should this effect be
stablished, morbidity and/or mortality would be favorably
mpacted.
As this study was a clinical trial, we were unable to label the
ells so as to ascertain the extent to which they trafficked to theeart. Some pre-clinical studies suggest that the level of cell
etention in the heart after intravenous infusion is very low
24). There are also data that suggest recently infarcted tissue
eleases injury signals that facilitate the trafficking of cells to the
amaged area (8). To the extent that minimal cells traffic to the
eart, paracrine factors released from the cells may be pivotal in
heir mechanism of action (36,39). Future experimental work
ill be required to resolve the mechanistic issues surrounding
he use of MSCs and, in particular, the role played by cell
elivery route and cell retention within the heart.
onclusions
his study was conducted to assess the safety of hMSCs after
I, and utilized a rigorous double-blind, placebo-controlled,
ose-ranging study design. Importantly, the study met its
rimary objective and demonstrated safety both with regard to
cute infusions of hMSCs as well as long-term absence of
ctopic tissue formation. Specific safety monitoring indicated
hat cell-treated patients, in fact, had improved outcomes with
egard to cardiac arrhythmias, pulmonary function, left ven-
ricular function, and symptomatic global assessment. These
ndings support the conduct of more extensive studies assess-
ng the value of allogeneic hMSCs for the treatment of
ardiovascular disorders.
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APPENDIX
or a list of participating centers and members of the Data Safety and
onitoring Board, please see the online version of this article.
